The AOC Platform: Antibody-Mediated RNA Delivery to Muscle

The Avidity Biosciences Antibody Oligonucleotide Conjugate (AOC) platform works by linking transferrin receptor 1 (TfR1)-targeting antibodies to RNA therapeutic payloads — either siRNA or antisense oligonucleotide (ASO) — to achieve muscle-selective delivery. This mechanism directly addresses the fundamental limitation of naked oligonucleotide therapies: insufficient uptake into skeletal and cardiac muscle tissue after systemic administration.

TfR1 is highly expressed on the surface of skeletal and cardiac muscle cells, making it a well-validated receptor for antibody-mediated endocytosis. By conjugating an oligonucleotide payload to a TfR1-targeting antibody, Avidity’s platform enables active intracellular delivery of the RNA therapeutic to muscle — the primary tissue affected in both myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). This is a mechanistic departure from PMO-based exon-skipping drugs such as eteplirsen and golodirsen, which rely on passive distribution and have faced scrutiny over muscle bioavailability.

The convergence of antibody engineering and RNA therapeutics in the AOC format represents a broader trend in biopharma: using established tissue-targeting biology to solve the delivery problem that has historically limited oligonucleotide drugs. According to WHO estimates, rare neuromuscular diseases collectively affect millions of patients globally, with DM1 and DMD among the highest-prevalence monogenic conditions in this category — yet both remain without disease-modifying therapies that address the underlying RNA pathology at scale.

AOC 1001 and Myotonic Dystrophy Type 1: DMPK Targeting and the MARINA Trial

AOC 1001 targets myotonic dystrophy type 1 (DM1) by using an RNAi payload to reduce toxic CUG repeat RNA produced by the DMPK gene. In DM1, an expanded CTG repeat in the 3′ UTR of the DMPK gene produces RNA transcripts containing CUG repeats that sequester the MBNL1 splicing factor, causing widespread splicing dysregulation across multiple tissues — most critically in skeletal muscle, cardiac muscle, and the central nervous system.

The therapeutic rationale is that reducing DMPK mRNA — and therefore the toxic CUG repeat RNA burden — should liberate sequestered MBNL1 protein, restoring normal splicing patterns across affected tissues. Rescue of MBNL1-regulated splicing events serves as the primary biomarker strategy in the MARINA clinical trial, allowing measurement of downstream therapeutic effect at the RNA level rather than relying solely on functional endpoints that can be confounded by disease heterogeneity.

“MBNL1 splicing rescue — not just DMPK knockdown — is the biomarker strategy that distinguishes AOC 1001’s clinical readout from earlier DM1 therapeutic attempts.”

The MARINA trial is the designated Phase 1/2 clinical study for AOC 1001 in DM1, registered on ClinicalTrials.gov. The trial design incorporates dose-escalation cohorts with biomarker-enriched endpoints, providing the clinical translation signals that would inform a Phase III protocol. DM1 is the most common adult-onset muscular dystrophy, and the absence of any approved disease-modifying therapy creates a clear regulatory pathway for a well-differentiated RNA therapeutic with mechanistic biomarker support.

Comparison to small molecule approaches for DM1 — including DMPK kinase inhibitors and splice-switching small molecules — highlights the AOC platform’s differentiation. Small molecules targeting the DMPK pathway have faced challenges with selectivity and tissue penetration. Splice-switching approaches using naked ASOs have demonstrated proof-of-concept in animal models but have been limited by oligonucleotide delivery to muscle at therapeutically relevant concentrations. The TfR1-mediated delivery mechanism of AOC 1001 is specifically designed to overcome this barrier.

AOC 1044 and Duchenne Muscular Dystrophy: Exon 44 Skipping for a Defined Patient Subset

AOC 1044 targets Duchenne muscular dystrophy (DMD) through an exon 44 skipping strategy designed for a defined subset of DMD patients whose mutations are amenable to restoration of the dystrophin reading frame by skipping exon 44. Dystrophin restoration — measured by quantity and localisation of dystrophin protein in muscle biopsies — is the primary therapeutic endpoint for AOC 1044.

The mechanistic distinction from PMO-based exon-skipping drugs is central to the AOC 1044 clinical and competitive narrative. Phosphorodiamidate morpholino oligomers (PMOs) such as eteplirsen (exon 51) and golodirsen (exon 53) have received accelerated approvals from the FDA based on dystrophin increases as a surrogate endpoint, but have faced ongoing scrutiny over the magnitude of dystrophin restoration achieved and the clinical benefit demonstrated. According to data reviewed by the FDA, the dystrophin levels achieved by approved PMO drugs have been modest, raising the question of whether higher dystrophin restoration — potentially achievable with superior muscle delivery — would translate to greater functional benefit.

The exon 44 skipping strategy addresses a defined subset of DMD patients — those with deletions in the exon 45–55 region or specific point mutations whose reading frame can be restored by skipping exon 44. Patient stratification by mutation type is a prerequisite for AOC 1044 clinical development, consistent with the precision medicine approach adopted across the DMD exon-skipping drug class. Regulatory precedent from prior exon-skipping approvals at the EMA and FDA provides a defined framework for the dystrophin restoration endpoint that AOC 1044 will need to meet or exceed.

Phase III Readiness: Clinical Translation Signals, Regulatory Designations, and Endpoint Strategy

Phase III readiness for both AOC 1001 and AOC 1044 depends on the convergence of IND-enabling preclinical data, Phase 1/2 dose-escalation results, regulatory designation status, and endpoint negotiation with agencies. For rare disease programs of this type, FDA Fast Track and Breakthrough Therapy designations are critical accelerators — they enable rolling review, more frequent agency interactions, and in some cases support for surrogate or biomarker-based primary endpoints.

For AOC 1001 in DM1, the MARINA trial provides the dose-escalation and biomarker data that would underpin a Phase III protocol. The use of MBNL1 splicing rescue as a pharmacodynamic readout gives the program a quantitative molecular endpoint that regulators can evaluate independently of functional measures, which in DM1 are complicated by multisystem disease involvement and patient heterogeneity. This biomarker strategy is analogous to the approach used in spinal muscular atrophy (SMA) programs, where SMN protein levels served as an early indicator of biological activity before functional endpoints were established.

For AOC 1044 in DMD, the Phase III pathway is shaped by the existing regulatory framework for exon-skipping drugs. The FDA’s accelerated approval pathway for DMD, using dystrophin as a surrogate endpoint, has been tested across multiple PMO drugs. AOC 1044’s differentiation argument — that TfR1-mediated delivery achieves meaningfully higher dystrophin restoration than naked PMOs — would need to be supported by comparative biomarker data from the Phase 1/2 program to justify a Phase III design that uses dystrophin as a primary endpoint or that seeks confirmatory evidence of clinical benefit.

Endpoint negotiation for both programs will also be influenced by patient advocacy engagement and natural history data. In DM1, the absence of validated functional endpoints that are sensitive to change over a trial duration of 12–24 months has historically complicated Phase III design. In DMD, the exon-specific patient stratification means that each exon-skipping program operates in a relatively small patient population, increasing the importance of biomarker-enriched designs and adaptive trial frameworks endorsed by bodies such as EMA.

IP Landscape and Acquisition Integration: What the Patent Record Should Reveal

The intellectual property landscape for Avidity Biosciences’ AOC platform spans at least four distinct patent families: AOC conjugation chemistry, TfR1 antibody sequences and engineering, oligonucleotide payload design (siRNA and ASO), and manufacturing methods for the conjugated molecule. Each of these layers represents both a defensive moat and a potential licensing or acquisition asset, making the IP record a critical input for competitive intelligence and deal evaluation.

Patent filings from Avidity Biosciences can be retrieved directly from WIPO‘s PatentScope, the USPTO’s Patent Full-Text Database, and the EPO’s Espacenet, using the assignee term “Avidity Biosciences.” Key claim categories to evaluate include: the structural definition of the TfR1 antibody moiety and its binding epitope; the linker chemistry connecting antibody to oligonucleotide; the sequence and chemical modification profile of the siRNA or ASO payload; and the manufacturing process claims that define the conjugation reaction and purification steps.

Acquisition integration context — including any corporate transactions, licensing agreements, or platform asset transfers relevant to Avidity’s pipeline — would be disclosed in SEC filings including 10-K annual reports, S-1 registration statements, and proxy statements. These filings contain pipeline disclosure language that can be used to track changes in asset ownership, co-development agreements, and the financial terms of any technology licensing that underpins the AOC platform’s freedom-to-operate position.

The manufacturing IP layer deserves particular attention in the acquisition integration context. AOC molecules combine the manufacturing complexity of monoclonal antibodies with the chemical synthesis requirements of modified oligonucleotides — a dual-modality manufacturing challenge that requires specialised conjugation infrastructure. Any acquisition or licensing transaction involving the AOC platform would need to address manufacturing technology transfer, which may be protected by separate process patents or trade secrets not visible in the published patent record.